Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction

Key clinical point: Similar outcomes but higher costs were seen for patients with hemophilia or von Willebrand disease undergoing anterior cruciate ligament (ACL) reconstruction, compared with controls.

Major finding: Total health care utilization within 30 days of ACL reconstruction was significantly greater for hemophilia A ($25,982) and von Willebrand disease ($16,445) patients, compared with controls ($12,887).

Study details: A retrospective study of 33 patients with hemophilia A, 3 with hemophilia B, and 63 with von Willebrand factor, as well as 103,478 controls, who all underwent ACL reconstruction.

Disclosures: The authors reported that they had no potential conflicts of interest to disclose.


Zale C et al. Knee. 2020;27(6):1729-34.